Details of the Drug Reposition

General Information of This Drug (ID: DM3A701)

Drug Name
IDP-122   DM3A701

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Primary cutaneous T-cell lymphoma DIS35WVW N.A. Approved [1]
Granuloma annulare DISMOUMI N.A. Approved [1]
Exanthem DISAFOQN N.A. Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Seborrhoeic dermatitis DISNWVJU EA81 Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Plaque psoriasis DISQX1LF EA90.0 Discontinued in Phase 2 [3]
Contact dermatitis DISQ3AU0 EK0Z Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors
3 Methylprednisolone N Acetylcysteine in Hepatic Resections
4 ClinicalTrials.gov (NCT01166126) Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV